A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

SU5416 (Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR)2. A Phase I dose escalation study was performed. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used as a pharmaco...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: O'Donnell, A, Padhani, A, Hayes, C, Kakkar, A J, Leach, M, Trigo, J M, Scurr, M, Raynaud, F, Phillips, S, Aherne, W, Hardcastle, A, Workman, P, Hannah, A, Judson, I
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group 2005
Onderwerpen:
Clinical Study
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361651/
https://ncbi.nlm.nih.gov/pubmed/16222321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602797
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items